Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer

Gastric cancer (GC) is the second leading cause of cancer-related mortality worldwide. The usual treatment of GC consists of surgery with additional adjuvant chemotherapy. In the present study, the feasibility and safety of adjuvant S-1 plus oxaliplatin (SOX) chemotherapy for patients with GC and th...

Descripción completa

Detalles Bibliográficos
Autores principales: YANG, LIN, YANG, YI, QIN, QIONG, ZHOU, AIPING, ZHAO, JIANJUN, WANG, JINWAN, SHU, CHANG, YUAN, XINGHUA, HU, SONGNIAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315063/
https://www.ncbi.nlm.nih.gov/pubmed/25663930
http://dx.doi.org/10.3892/ol.2014.2821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315063/
https://www.ncbi.nlm.nih.gov/pubmed/25663930
http://dx.doi.org/10.3892/ol.2014.2821

Ejemplares similares